Roche catapults Thomas Schinecker to chief of diagnostics unit
One day after the FDA sanctioned the accelerated approval of Roche’s latest antibody-drug conjugate, the Swiss drugmaker has unveiled the new head of its $13 billion diagnostics unit.
Roche’s diagnostics arm generated CHF 12.9 billion ($13 billion) in sales last year. It sells a myriad of tests for blood, HPV, cancer and diabetes and is driven by its centralized and point of care solutions business. The head of this well-performing unit — Thomas Schinecker — is being promoted to CEO of Roche Diagnostics, and will begin his tenure from August 1, the company said on Tuesday.
Roche has been looking for an internal, permanent replacement for Roland Diggelmann, who left his post last August. Schinecker started out as a trainee for Roche Diagnostics in 2003, and has held a plethora of management positions in marketing & sales and product development.
Meanwhile, Roche board member Peter Voser — who has been with the company since 2011 — has elected to step down to focus on his role as interim CEO of ABB, a position he is manning after Ulrich Spiesshofer left the robotics and automation company in April. In addition, Roche’s head of group communications, Stephan Feldhaus, is also leaving, and will be replaced by Barbara Schaedler, who is currently head of public affairs at private energy company E ON SE.